Botanix Pharma (ASX:BOT)

  • Symbol:ASX:BOT
  • Sector:Healthcare
  • Industry:Biotechnology
  • CEO:Vince Ippolito
  • Founded:2002

Botanix Pharma (ASX:BOT) Stock Price

Botanix Pharma (ASX:BOT) Company Overview

Botanix Pharma is an Australian medical dermatology company engaged in the development of cannabinoid-based products for the treatment of a range of skin conditions and are working to get the first cannabinoid products approved by the FDA. If successful, they could dominate a multi-billion dollar dermatology market which has seen few new products approved in the last 20 years.

All products made by Botanix Pharma utilise synthetic CBD in conjunction with PermetrexTM skin delivery technology. PermetrexTM is a dermal delivery formulation technology that allows 10 to 20 times more of the active ingredient to get through the skin to better treat the disease. BOT has exclusive rights to this technology, developed by Dr Eugene Cooper, for all drugs that treat dermatological conditions.

The first two products off the rank target the treatment of Acne (BTX1503) and Atopic Dermatitis (BTX1204). Both drugs are currently in Phase II trials, with outcomes due in late 2019. As it stands right now, there are no cannabis-based products approved for these markets and no-one else is studying the impact of CBD-based products on these conditions.

Should BOT deliver successful endpoints on the Phase II trials for their leading assets, then the most likely outcome from there would be a licensing deal with a global BIG Pharma player that would deliver significant upfront cash flow, and medium-term licensing royalties post successful Phase III study outcomes.

Botanix Pharma (ASX:BOT) Financials

More From Botanix Pharma...

The Best Marijuana Stocks to Watch in 2019
Riding High: Exclusive Interview with Botanix Pharma's Leadership Team
June 2019 – Cannabis Stocks still Under Pressure from the Bears
And You Thought Money Doesn't Grow On Trees
Pushing the Limits – Valens Scales Up Extraction Capacity and Receives TSXV Listing Approval
Botanix Creates New Anti-Bacterial Cannabis Drug
6 Additional Aussie cannabis stocks to watch in 2019 – cannpal, botanix, thc asx and more!

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Matthew Callahan
Founder and Executive Director
Matt Callahan is an experienced life sciences executive, as well as being the founding CEO of iCeutica Inc and Churchill Pharma Inc. He has more than 20 years legal, IP and investment management experience, and is a director of Glycan Bioscience LLC.

Callahan has also worked as an investment director for two venture capital firms focused on investing in life sciences, clean technology and other sectors.
Vince Ippolito
President & Executive Chairman
Vince Ippolito is a leading pharmaceutical expert who has over 30 years of experience in the industry, including more than 20 years in dermatology.

Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine, along with playing a leading role in two of the largest dermatology acquisitions—with a combined valuation of $7.8 billion—completed in the past decade.
Dr Bill Bosch
Executive Director & Chief Scientific Officer
Dr Bill Bosch is a seasoned pharmaceutical executive with more than 20 years of experience in the industry, with a specific focus on the applications of nano technology to drug product development.

He is a co-inventor of the NanoCrystal® and SoluMatrix™ technologies, along with being instrumental to the development of the 3 FDA approved products that make use of his delivery system.
Ric Peterson
Chief Financial Officer
Ric Peterson has extensive experience with the dermatology field, capital markets and corporate governance. Previously, he held the position of CFO at Dermavant Sciences, and also served as a CFO at dermatology companies like Sienna Biopharmaceuticals, Novan and Medicis Pharmaceutical.

In these roles, Peterson oversaw duties relating to finance, business development, business operations and information technology.
Dr Michael Thurn
Executive Director
Michael Thurn is an experienced senior executive with 15 years of managerial and Board experience. He has a Doctor of Philosophy from University of Technology Sydney and was a Postdoctoral Research fellow at the Australian Institute of Marine Science.

Thurn has a background in drug regulation and the biopharmaceutical industry, which has included senior roles with both listed and private companies. He has worked extensively with life science start-ups across a range of technology platforms, as well as having experience in drug discovery, preclinical and clinical development.